Q3 Earnings Estimate for Longeveron Issued By Zacks Research

Longeveron Inc. (NASDAQ:LGVN) – Equities research analysts at Zacks Research cut their Q3 2026 EPS estimates for Longeveron in a note issued to investors on Thursday, August 13th. Zacks Research analyst B. Sorensen now anticipates that the company will post earnings per share of ($0.17) for the quarter, down from their previous estimate of ($0.16). The consensus estimate for Longeveron’s current full-year earnings is ($0.68) per share. Zacks Research also issued estimates for Longeveron’s Q4 2026 earnings at ($0.17) EPS, FY2026 earnings at ($0.72) EPS, FY2027 earnings at ($0.58) EPS and FY2028 earnings at ($0.56) EPS.

Several other analysts also recently commented on the stock. Maxim Group downgraded shares of Longeveron from a “buy” rating to a “hold” rating in a research report on Monday, May 11th. Wall Street Zen downgraded Longeveron from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Weiss Ratings lowered shares of Longeveron from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 11th. Finally, HC Wainwright cut their target price on Longeveron from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, May 4th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Longeveron has a consensus rating of “Hold” and an average price target of $8.00.

Longeveron Price Performance

Shares of NASDAQ LGVN opened at $0.82 on Thursday. The company has a market capitalization of $25.61 million, a P/E ratio of -0.83 and a beta of -0.31. The business’s 50-day moving average price is $0.71 and its two-hundred day moving average price is $0.77. Longeveron has a one year low of $0.47 and a one year high of $1.23.

Longeveron (NASDAQ:LGVN) last released its earnings results on Wednesday, August 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.01). Longeveron had a negative return on equity of 223.19% and a negative net margin of 1,977.59%.The company had revenue of $0.29 million during the quarter, compared to analysts’ expectations of $0.33 million.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Longeveron stock. ADAR1 Capital Management LLC purchased a new stake in Longeveron Inc. (NASDAQ:LGVN) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 200,000 shares of the company’s stock, valued at approximately $208,000. ADAR1 Capital Management LLC owned about 0.86% of Longeveron as of its most recent SEC filing. 10.01% of the stock is owned by hedge funds and other institutional investors.

Longeveron Company Profile

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.